SCHEMBL4604536

SCHEMBL4604536

CCC(=O)Nc1ccc(COc2ccccc2OC(F)(F)F)cc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.57
RXRB P28702 1/20 0.57
RXRG P48443 1/20 0.57
KDM4E B2RXH2 5/20 0.48
ALDH1A1 P00352 4/20 0.48
HSD17B10 Q99714 2/20 0.48
PKM P14618 2/20 0.46
RORC P51449 1/20 0.45
DVL1 O14640 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
IGF2BP2 Q9Y6M1 1/20 0.43
GAA P10253 1/20 0.42
LTC4S Q16873 1/20 0.42
CTSV O60911 1/20 0.41
CTSL P07711 1/20 0.41
F2R P25116 1/20 0.41
FOLH1 Q04609 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4605839 0.87 RXRA (0.57) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL4606034 0.83 IGF2BP2 (0.51) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL4605959 0.83 KDM4E (0.43) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL1827003 0.83 PTGDR2 (0.47) KDM4EALDH1A1PKMDVL1MRGPRX4
SCHEMBL1823645 0.83 KDM4E (0.42) KDM4EALDH1A1PKMDVL1MRGPRX4
SCHEMBL1825080 0.83 MRGPRX4 (0.56) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL4606969 0.81 DVL1 (0.56) KDM4EALDH1A1HSD17B10PKMDVL1
SCHEMBL4604701 0.81 IGF2BP2 (0.48) KDM4EALDH1A1HSD17B10PKMIGF2BP2
SCHEMBL1825124 0.81 MRGPRX4 (0.57) RXRARXRBRXRGKDM4EALDH1A1
SCHEMBL1824517 0.81 PTGDR2 (0.49) KDM4EALDH1A1PKMMRGPRX4IGF2BP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1914152-B New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB 2010-06-09 CN disclosed
EP-1720825-B1 ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS ACTIVE BIOTECH AB (SE) 2008-07-09 EP disclosed
CN-1914152-A New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2007-02-14 CN disclosed
EP-1720825-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF Active Biotech AB (SE) 2006-11-15 EP disclosed
US-7074831-B2 Compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2006-07-11 US disclosed
US-20050187297-A1 New compounds, methods for their preparation and use thereof ACTIVE BIOTECH AB (SE) 2005-08-25 US disclosed
WO-2005075410-A1 NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF ACTIVE BIOTECH AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187297-A1 New compounds, methods for their preparation and use thereof MALT1, TPMT, FUCA1 RXRA 846/4885RXRB 667/4885RXRG 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.